Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionVaccine composed of respiratory syncytial virus (RSV) sF antigen plus a synthetic glucopyranosyl lipid A (GLA) adjuvant
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsPrevent respiratory syncytial virus (RSV); Treat respiratory syncytial virus (RSV) infection
Regulatory Designation
PartnerImmune Design Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today